Insmed is set to challenge the Duchenne muscular dystrophy (DMD) treatment space with its innovative gene therapy asset, INS1201.

Altruism values for treatments of rare, severe pediatric diseases have not been estimated. This study found the altruism value for a hypothetical new Duchenne muscular dystrophy treatment to be $80 ...

If you want to get healthy in the new year, it’s important to focus on all body parts, including your mouth. Anne Clemons, ...

Wave Life Sciences shows promising data in genetic mutation treatments, with GSK collaborations and strong financial footing.

Capricor Therapeutics seeks US FDA approval for deramiocel for the treatment of Duchenne muscular dystrophy: San Diego Saturday, January 4, 2025, 15:00 Hrs [IST] Capricor Therapeu ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology firm specializing in innovative cell and exosome-based therapies for rare diseases, finalized the submission of its Biologics License ...